

Stallergenes SAS (GENP) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/S6B1C5D25BFEN.html
Date:	March 1, 2016
Pages:	47
Price:	US\$ 125.00
ID:	S6B1C5D25BFEN

Stallergenes SAS (GENP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Stallergenes SAS (Stallergenes), a subsidiary of Stallergenes Greer is a biopharmaceutical company, which provides treatments for allergy-related respiratory diseases. The company develops diagnostic tests and products with principal focus on allergies. The company offers treatment for important respiratory diseases, which include severe rhino conjunctivitis and rhinitis, and allergic asthma. Stallergenes provides allergen immunotherapy in various dosage forms including injectable or subcutaneous injections, liquid sublinguals and solid sublinguals. Its research and development activities involve development of candidate products, laboratory research, clinical development and regulatory activities. The company distributes its products to various countries in North America, Europe, Africa; Asia and in Australia. Stallergenes is headquartered in Antony, France.

Stallergenes SAS Key Recent Developments

Feb 10, 2016: Michele Antonelli Appointed President Of Stallergenes Sas & Executive VP Head Of Europe & Row

Feb 01, 2016: Stallergenes Greer Announces Resumption Of Manufacturing At Its Antony Plant

Feb 01, 2016: Tibor Nemes Appointed Global Head of Technical Operations: Stallergenes Greer

Dec 07, 2015: Stallergenes Greer PLC: Recall of Allergy Immunotherapy Products

Dec 02, 2015: Temporary Suspension Of Manufacturing At Stallergenes Antony Plant

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

Stallergenes SAS - Key Facts

Stallergenes SAS - Key Employees

Stallergenes SAS - Key Employee Biographies

Stallergenes SAS - Major Products and Services

Stallergenes SAS - Pharmaceutical Pipeline Products Data

Stallergenes SAS, Pipeline Products by Therapy Area

Stallergenes SAS, Pipeline Products by Development Phase

Stallergenes SAS - History

Stallergenes SAS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Stallergenes SAS - Business Description
Stallergenes SAS - Corporate Strategy
Stallergenes SAS - SWOT Analysis
SWOT Analysis - Overview
Stallergenes SAS - Strengths
Strength - Portfolio of Allergen Immunotherapy Products
Strength - Revenue Driven by Strong Performance of All Administration Routes
Strength - Strong In-house Research Capabilities
Stallergenes SAS - Weaknesses
Weakness - Product Recall
Stallergenes SAS - Opportunities
Opportunity - Product Pipeline
Opportunity - Business Initiatives
Opportunity - Market Potential for Treatments for Allergic Rhinitis
Stallergenes SAS - Threats
Threat - Cost Containment Pressures
Threat - Uncertain R&D Outcomes
Threat - Intense Competition
Stallergenes SAS - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Stallergenes SAS, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Stallergenes SAS, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Stallergenes SAS, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Feb 10, 2016: Michele Antonelli Appointed President Of Stallergenes Sas & Executive VP Head Of Europe & Row
Feb 01, 2016: Tibor Nemes Appointed Global Head of Technical Operations: Stallergenes Greer
Feb 01, 2016: Stallergenes Greer Announces Resumption Of Manufacturing At Its Antony Plant
Dec 07, 2015: Stallergenes Greer PLC: Recall of Allergy Immunotherapy Products
Dec 02, 2015: Temporary Suspension Of Manufacturing At Stallergenes Antony Plant
Jul 22, 2015: Stallergenes: Strong Revenue Growth In H1 2015 Exceeding Targets
Apr 21, 2015: Strong Sales Growth In Q1 2015 (up 7.5%) Exceeding Targets
Mar 03, 2015: 2.5% growth in net sales & EBITA outperformed 2014 targets

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Stallergenes SAS, Key Facts
Stallergenes SAS, Key Employees
Stallergenes SAS, Key Employee Biographies
Stallergenes SAS, Major Products and Services
Stallergenes SAS, Number of Pipeline Products by Therapy Area
Stallergenes SAS, Number of Pipeline Products by Development Stage
Stallergenes SAS, Pipeline Products By Therapy Area and Development Phase
Stallergenes SAS, History
Stallergenes SAS, Subsidiaries
Stallergenes SAS, Key Competitors
Stallergenes SAS, Ratios based on current share price
Stallergenes SAS, Annual Ratios
Stallergenes SAS, Interim Ratios
Stallergenes SAS, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Stallergenes SAS, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Stallergenes SAS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Stallergenes SAS, Pipeline Products by Therapy Area
Stallergenes SAS, Pipeline Products by Development Phase
Stallergenes SAS, Performance Chart (2010 - 2014)
Stallergenes SAS, Ratio Charts
Stallergenes SAS, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Stallergenes SAS, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Sanofi-Aventis AB
NicOx S.A.
Vetoquinol SA
Ipsen S.A.
Onxeo SA
DBV Technologies S.A.

I would like to order:

Product name: Stallergenes SAS (GENP) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/S6B1C5D25BFEN.html>
Product ID: S6B1C5D25BFEN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/S6B1C5D25BFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**